Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01208948 | Clinical Trial on Alpha Lipoic Acid in Diabetic Macular Edema | PHASE3 | COMPLETED | 520 | — | — | Jul 1, 2000 | Dec 1, 2005 | Sep 24, 2010 | 1 | Germany |
| Arm | Type | Description |
|---|---|---|
| Alpha lipoic acid 600 mg | ACTIVE_COMPARATOR | - |
| placebo pill | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| 1,2 dithiolane 3 valeric acid | DRUG | 600 mg alpha lipoic acid per day |
Inclusion Criteria: * Diabetes type II, mild non proliferative diabetic retinopathy, * Microalbuminuria \> 30 mg/L Exclusion Criteria: Ophthalmic exclusion criteria * severe non-proliferative or proliferative diabetic retinopathy * Macular edema * Eye diseases interfering with the examinations o...